Work

Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351)

Year: 2017

Type: article

Source: Neurology

DOI: 10.1212/wnl.88.16_supplement.p6.351

Authors: Gavin Giovannoni, Kottil Rammohan, Stuart Cook, Giancarlo Comi, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Fernando Dangond, Christine Hicking

Institutions: Queen Mary University of London, Blizard Institute, Ohio State University Hospital, Rutgers, The State University of New Jersey, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Copenhagen University Hospital, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Inflammation Research International Center, EMD Serono, Inc. (United States), Merck KGaA, Darmstadt (Germany)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2805137201

FWCI:

Cites:

Cited by: 2

Related to: 10